Advertisement
Organisation › Details
SV Health Investors (Group)
SV Health Investors is a leading healthcare fund manager committed to investing in tomorrow’s healthcare breakthroughs. SV invests across stages, geographic regions, and sectors, with expertise spanning biotechnology, dementia, healthcare growth, healthcare technology and public equities. With approximately $2.2B in assets under management and a truly transatlantic presence with offices in Boston and London, SV has built an extensive network of talented investment professionals and experienced industry veterans. Since its founding in 1993, SV has invested in more than 175 companies with more than 75 of these having achieved successful acquisitions or IPOs. Historically, SV managed funds have been diversified across the three sectors. However, the firm’s seventh vintage of core funds is separated into three distinct vehicles; the SV7 Impact Medicine Fund forms and funds early-stage biotechnology companies developing precision medicines, the Growth Fund accelerates growth-stage healthcare services, medical products and digital health companies and the Medtech Convergence Fund specialises in novel medical device and remote-monitoring technologies. Alongside their core funds, SV manages the Dementia Discovery Fund, focused on discovering and developing novel therapeutics for dementia, and the International Biotechnology Trust plc, a publicly-traded investment trust. *
Start | 2017-04-10 renamed | |
Predecessor | SV Life Sciences (SVLS) (Group) | |
Industry | venture capital | |
Industry 2 | LIFE SCIENCES | |
Person | Ross, Mike (SV Health Investors 202009 Managing Partner) | |
Person 2 | Burgess, Daniel (Dan) (Pulmocide 202105 CEO + Venture Partner at SV Health Investors before Rempex + Mpex) | |
Region | London, Greater London | |
Country | United Kingdom (GB) | |
Street | 71 Kingsway | |
City | WC2B 6ST London | |
Tel | +44-20-7421-7070 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | B: 11 to 50 (2015-12-02) |
Currency | USD | |
Annual sales | 2,200,000,000 (assets, managed (2020) 2020-09-15) | |
* Document for »About Section«: Cellinta Ltd.. (9/15/20). "Press Release: Launch of Cellinta and Appointment of Dr Soraya Bekkali as CEO". London. | ||
Record changed: 2023-11-23 |
Advertisement
More documents for SV Health Investors (Group)
- [1] Eyebiotech Ldt.. (2/22/22). "Press Release: EyeBio Raises $65M in Series A Funding to Develop New Generation of Eye Disease Therapies". London & New York, NY....
- [2] LoQus23 Therapeutics Ltd.. (11/23/21). "Press Release: LoQus23 Therapeutics Exits Stealth with £11.5 Million Seed Financing from the Dementia Discovery Fund and Novartis Venture Fund". Cambridge....
- [3] Mestag Therapeutics Ltd.. (4/20/21). "Press Release: Mestag Therapeutics Launches with Seed Financing of $11 Million to Develop Therapeutics Targeting Activated Fibroblast Populations across Inflammatory Disease and Cancer". Cambridge....
- [4] Cellinta Ltd.. (9/15/20). "Press Release: Launch of Cellinta and Appointment of Dr Soraya Bekkali as CEO". London....
- [5] Ervaxx Ltd.. (11/6/19). "Press Release: Ervaxx Launches to Pioneer the Use of Dark Antigens for the Development of Off-the-Shelf Cancer Vaccines and T-cell Receptor-based Immunotherapies". London....
- [6] Cancer Research UK. (7/2/19). "Press Release: Cancer Research UK Forms Collaboration with SV Health Investors to Accelerate Development of Cancer Medicines"....
- [7] Sitryx Therapeutics Ltd.. (10/8/18). "Press Release: New Biopharmaceutical Company Sitryx Launches with $30 Million Fundraising to Develop Disease Modifying Therapeutics in Immunometabolism". Oxford....
- [8] Immuneering Corporation. (6/18/18). "Press Release: The Dementia Discovery Fund and Immuneering Announce a Research Collaboration to Identify Novel Drug Targets and Drug Candidates for Alzheimer's Disease". Cambridge, MA & London....
- [9] EBD Group. (10/13/17). "Press Release: BIO-Europe 2017 to Bring 3,800 Life Science Leaders to Berlin November 6–8". Carlsbad, CA & Berlin....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top